Table 3

Unadjusted ORsa for prostate cancer by control quintileb of plasma antioxidant concentration: all cases and aggressive cases only

OR (95% CI)
All cases, by quintile (n = 578 sets)Aggressive cases, by quintile (n = 259 sets)
12345P, trend12345P, trend
α-Carotene1.001.110.971.140.770.091.001.311.021.251.020.82
(0.81–1.54)(0.70–1.35)(0.82–1.58)(0.54–1.10)(0.80–2.15)(0.62–1.70)(0.77–2.04)(0.61–1.72)
β-Cryptoxanthin1.000.850.870.880.800.291.000.680.630.860.700.54
(0.61–1.18)(0.62–1.21)(0.64–1.21)(0.57–1.11)(0.41–1.14)(0.38–1.03)(0.53–1.39)(0.42–1.16)
Lutein1.001.011.081.091.100.631.001.361.291.391.280.60
(0.72–1.42)(0.77–1.51)(0.78–1.52)(0.73–1.65)(0.82–2.26)(0.77–2.18)(0.85–2.28)(0.66–2.47)
Lycopene1.000.890.900.870.750.121.000.640.710.700.56c0.05
(0.64–1.23)(0.65–1.24)(0.63–1.19)(0.54–1.06)(0.40–1.03)(0.44–1.15)(0.44–1.10)(0.34–0.92)
α-Tocopherol1.001.041.091.171.060.701.000.970.811.020.640.11
(0.75–1.43)(0.78–1.51)(0.85–1.62)(0.76–1.48)(0.61–1.54)(0.50–1.32)(0.63–1.66)(0.38–1.07)
α-Tocopherol1.000.910.900.870.980.891.000.910.830.791.000.96
(0.67–1.23)(0.65–1.24)(0.64–1.19)(0.71–1.35)(0.58–1.42)(0.51–1.33)(0.49–1.29)(0.62–1.60)
Retinol1.001.081.371.211.560.021.001.381.441.261.270.64
(0.76–1.53)(0.97–1.92)(0.84–1.74)(1.07–2.27)(0.84–2.27)(0.86–2.40)(0.74–2.15)(0.73–2.23)
  • a Cases and controls were matched on age, follow-up time at risk, and smoking status. ORs adjusted for exercise frequency, body mass index, plasma total cholesterol, alcohol, and multivitamin supplement use were similar to the unadjusted estimates.

  • b Quintile cutoff points (in ng/ml) were as follows: α-carotene, 34.6, 50.4, 67.8, and 103.3; β-cryptoxanthin, 36.9, 53.5, 75.2, and 111.4; lutein, 60.8, 79.3, 101.8, and 147.0; lycopene, 261.7, 353.6, 442.9, and 580.1; α-tocopherol, 8,564, 10,204, 11,887, and 14,441; γ-tocopherol, 1,254, 1,627, 1,990, and 2,530; retinol, 450.0, 523.5, 587.1, and 679.9.

  • c P = 0.02.